Thyroid dysfunction in patients (pts) with metastatic renal cell cancer (RCC) treated with sorafenib

被引：0
|
作者：
Clement, P.
Wolter, P.
Stefan, C.
Decallonne, B.
Dumez, H.
Wildiers, H.
Schoffski, P.
机构：
[1] UZ Leuven, Louvain, Belgium
[2] Katholieke Univ Leuven Hosp, Louvain, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16145
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Sunitinib in patients (pts) with unresectable primary renal cell carcinoma (RCC)
    Wood, L.
    Garcia, J. A.
    Elson, P.
    Salas, R. N.
    Lane, B. R.
    Klein, E.
    Stephenson, A.
    Dreicer, R.
    Campbell, S. C.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Sorafenib rechallenge in patients with metastatic renal cell carcinoma
    Nozawa, Masahiro
    Yamamoto, Yutaka
    Minami, Takafumi
    Shimizu, Nobutaka
    Hatanaka, Yuji
    Tsuji, Hidenori
    Uemura, Hirotsugu
    BJU INTERNATIONAL, 2012, 110 (6B) : E228 - E234
  • [43] Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)
    Bregni, Marco
    Ciceri, Fabio
    Peccatori, Jacopo
    JOURNAL OF CANCER, 2011, 2 : 347 - 349
  • [44] A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC)
    Amato, R. J.
    Harris, P.
    Dalton, M.
    Khan, M.
    Alter, R.
    Zhai, Q.
    Brady, J. R.
    Jac, J.
    Hauke, R.
    Srinivas, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] A phase II trial of intra-patient dose escalated-sorafenib in patients (pts) with metastatic renal cell cancer (MRCC)
    Amato, R. J.
    Jac, J.
    Harris, P.
    Dalton, M.
    Saxena, S.
    Monzon, F.
    Zhai, J.
    Brady, J.
    Willis, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Long-term sorafenib (SOR) safety profile in >700 patients (pts) with renal-cell carcinoma (RCC) treated for 12 to 42 months (mos)
    Grimm, M-O
    Hutson, T. E.
    Procopio, G.
    Escudier, B.
    Negrier, S.
    Knox, J. J.
    Keilholz, U.
    Szczylik, A.
    Kalmus, J.
    Strauss, U. P.
    Brueckner, A.
    Bokemeyer, C.
    Jaeger, E.
    ONKOLOGIE, 2010, 33 : 58 - 59
  • [47] A phase II study of everolimus (E) and sorafenib (S) in patients (PTS) with metastatic differentiated thyroid cancer who have progressed on sorafenib alone
    Brose, Marcia S.
    Troxel, Andrea B.
    Yarchoan, Mark
    Cohen, Aaron Benjamin
    Harlacker, Kathleen
    Dyanick, Nikolas A.
    Posey, Zakkiyya A.
    Makani, Ramkrishna
    Prajapati, Parna
    Zifchak, Larisa M.
    Grande, Carolyn
    Squillante, Christian Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] THYROID-STIMULATING HORMONE (TSH) LEVELS IN PATIENTS WITH METASTATIC RENAL CELL CANCER TREATED WITH SUNITINIB
    Vassileiadis, T.
    Kontovinis, L.
    Pazaitou, K.
    Kontovini, M.
    Mouratidou, D.
    Papazisis, K. T.
    ANNALS OF ONCOLOGY, 2010, 21 : 289 - 289
  • [49] Pharmacokinetics (PK) and efficacy of axitinib in patients (pts) with sorafenib-refractory metastatic renal cell carcinoma (mRCC)
    Dutcher, Janice
    Garrett, May
    Wilding, George
    Stadler, Walter M.
    Pithavala, Yazdi
    Kim, Sinil
    Tarazi, Jamal
    Rixe, Olivier
    Rini, Brian I.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [50] Associations of dietary fructose with survival of patients (pts) with metastatic cancer of the urothelium (UC) and renal cell carcinoma (RCC) on immune checkpoint blockade (ICB)
    Badri, Anas
    Guercio, Brendan John
    Ratna, Neha
    Gavrilov, David
    Metzker, Nicholina
    Duzgol, Cihan
    Teo, Min Yuen
    Regazzi, Ashley M.
    Supplice, Lauren
    Funt, Samuel A.
    Aggen, David H.
    Voss, Martin H.
    Carlo, Marie Isabel
    Shah, Neil J.
    Motzer, Robert J.
    Bajorin, Dean F.
    Rosenberg, Jonathan E.
    Lee, Chung-Han
    Kotecha, Ritesh R.
    Iyer, Gopa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345